859 related articles for article (PubMed ID: 3004784)
1. Disparate effects of the calcium-channel blockers, nifedipine and verapamil, on alpha 2-adrenergic receptors and thromboxane A2-induced aggregation of human platelets.
Johnson GJ; Leis LA; Francis GS
Circulation; 1986 Apr; 73(4):847-54. PubMed ID: 3004784
[TBL] [Abstract][Full Text] [Related]
2. Effect of the calcium-entry blocking agent nifedipine on activation of human platelets and comparison with verapamil.
Han P; Boatwright C; Ardlie NG
Thromb Haemost; 1983 Aug; 50(2):513-7. PubMed ID: 6314581
[TBL] [Abstract][Full Text] [Related]
3. Adenosine potentiates the inhibitory effects of calcium channel antagonists on human platelet aggregation induced by thromboxane A2 or U46619.
Johnson GJ; Leis LA; Francis GS
Thromb Res; 1990 Jul; 59(1):139-48. PubMed ID: 2399526
[TBL] [Abstract][Full Text] [Related]
4. Dihydropyridine agonist Bay K 8644 inhibits platelet activation by competitive antagonism of thromboxane A2-prostaglandin H2 receptor.
Johnson GJ; Dunlop PC; Leis LA; From AH
Circ Res; 1988 Mar; 62(3):494-505. PubMed ID: 2449295
[TBL] [Abstract][Full Text] [Related]
5. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.
Ohkubo S; Nakahata N; Ohizumi Y
Br J Pharmacol; 1996 Mar; 117(6):1095-104. PubMed ID: 8882602
[TBL] [Abstract][Full Text] [Related]
6. Effects of verapamil and nisoldipine on human platelets: in vivo and in vitro studies.
Jones CR; Pasanisi F; Elliott HL; Reid JL
Br J Clin Pharmacol; 1985 Sep; 20(3):191-6. PubMed ID: 2994701
[TBL] [Abstract][Full Text] [Related]
7. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
Patscheke H; Stegmeier K
Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
[TBL] [Abstract][Full Text] [Related]
8. Studies of alpha 2-adrenergic receptors of intact and functional washed human platelets by binding of 3H-dihydroergocryptine and 3H-yohimbine--correlation of 3H-yohimbine binding with the potentiation by adrenaline of ADP-induced aggregation.
Lanza F; Cazenave JP
Thromb Haemost; 1985 Aug; 54(2):402-8. PubMed ID: 3001964
[TBL] [Abstract][Full Text] [Related]
9. Benzodiazepines inhibit human platelet activation: comparison of the mechanism of antiplatelet actions of flurazepam and diazepam.
Romstedt K; Huzoor-Akbar
Thromb Res; 1985 May; 38(4):361-74. PubMed ID: 2990062
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
11. Antithrombogenic effects of calcium channel blockers: synergism with prostacyclin and thromboxane synthase inhibitors.
Onoda JM; Sloane BF; Honn KV
Thromb Res; 1984 Jun; 34(5):367-78. PubMed ID: 6377570
[TBL] [Abstract][Full Text] [Related]
12. Binding of an 125I-labeled thromboxane A2/prostaglandin H2 receptor antagonist to washed canine platelets.
Mais DE; Kochel PJ; Saussy DL; Halushka PV
Mol Pharmacol; 1985 Aug; 28(2):163-9. PubMed ID: 2991736
[TBL] [Abstract][Full Text] [Related]
13. Interaction of verapamil with human platelet alpha-adrenergic receptors.
Barnathan ES; Addonizio VP; Shattil SJ
Am J Physiol; 1982 Jan; 242(1):H19-23. PubMed ID: 6277203
[TBL] [Abstract][Full Text] [Related]
14. Sevoflurane inhibits human platelet aggregation and thromboxane A2 formation, possibly by suppression of cyclooxygenase activity.
Hirakata H; Ushikubi F; Toda H; Nakamura K; Sai S; Urabe N; Hatano Y; Narumiya S; Mori K
Anesthesiology; 1996 Dec; 85(6):1447-53. PubMed ID: 8968193
[TBL] [Abstract][Full Text] [Related]
15. Selective modulation of the human platelet thromboxane A2/prostaglandin H2 receptor by eicosapentaenoic and docosahexaenoic acids in intact platelets and solubilized platelet membranes.
Parent CA; Lagarde M; Venton DL; Le Breton GC
J Biol Chem; 1992 Apr; 267(10):6541-7. PubMed ID: 1532390
[TBL] [Abstract][Full Text] [Related]
16. Effects of verapamil and diltiazem on human platelet function.
Addonizio VP; Fisher CA; Strauss JF; Wachtfogel YT; Colman RW; Josephson ME
Am J Physiol; 1986 Mar; 250(3 Pt 2):H366-71. PubMed ID: 3006516
[TBL] [Abstract][Full Text] [Related]
17. Thromboxane A2/prostaglandin H2 mobilizes calcium in human blood platelets.
Brace LD; Venton DL; Le Breton GC
Am J Physiol; 1985 Jul; 249(1 Pt 2):H1-7. PubMed ID: 3925795
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human platelet aggregation and cytoplasmic calcium response by calcium antagonists: studies with aequorin and quin2.
Ware JA; Johnson PC; Smith M; Salzman EW
Circ Res; 1986 Jul; 59(1):39-42. PubMed ID: 3089642
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin F2 alpha antagonizes thromboxane A2-induced human platelet aggregation.
Hung SC; Ghali NI; Venton DL; Le Breton GC
Prostaglandins; 1982 Aug; 24(2):195-206. PubMed ID: 6293001
[TBL] [Abstract][Full Text] [Related]
20. Antagonism of U46619-induced aggregation of human and canine platelets by four TXA2 receptor antagonists.
Bush LR; Smith SG
Thromb Res; 1986 Nov; 44(3):377-89. PubMed ID: 2948294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
